Key facts
- OrphAI Therapeutics’s last known valuation is $300.0M.
- It has raised $154.5M; the latest was Later Stage VC ($56.5M) in Oct 2024.
- Notable investors include YuanBio Venture Capital, Yonghua Capital, 4Catalyzer, Albany Capital (Australia), Gravity Ventures (Korea) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for OrphAI Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OrphAI Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OrphAI Therapeutics
Developer of a precision therapeutics technology designed to treat cancer and rare diseases. The company's technology accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics and combinational drug screening with deep learning to match clinical drugs, enabling doctors to treat diseases by providing significant therapeutic benefits for patients.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2013
- Employees
- 16
- Website
- orphai-therapeutics.com/
- Ownership
- Privately Held (backing)
OrphAI Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrphAI Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrphAI Therapeutics in its N-PORT filings yet. We sweep new filings monthly.